Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $56.33.

AGIO has been the subject of a number of research analyst reports. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Raymond James reiterated an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AGIO. Caxton Associates LP grew its holdings in Agios Pharmaceuticals by 0.7% during the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after purchasing an additional 264 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock worth $539,000 after acquiring an additional 688 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter worth about $37,000. Finally, Quest Partners LLC purchased a new position in Agios Pharmaceuticals in the second quarter valued at about $40,000.

Agios Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ:AGIO opened at $32.19 on Friday. The company has a market cap of $1.84 billion, a P/E ratio of 2.83 and a beta of 0.87. The business has a fifty day simple moving average of $47.63 and a 200-day simple moving average of $45.74. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.